Drug intelligence / Profile preview

BIA 5-1058 + furosemide

Development stage
Unknown
Lead developer
Bial
Modality
Small Molecules
Administration
Oral
01

Overview

**BIA 5-1058 + furosemide** is a combination drug regimen investigated primarily for the treatment of pulmonary arterial hypertension (PAH). **BIA 5-1058**, also known as **zamicastat**, is an experimental small molecule developed to modulate cardiovascular disease by inhibiting dopamine beta-hydroxylase (DBH), resulting in reduced sympathetic nervous system activity[3][5]. **Furosemide** is a well-established loop diuretic primarily used to treat edema and hypertension by inhibiting sodium and chloride reabsorption in the kidney's loop of Henle[7]. The combination is investigated because PAH often requires both modulation of sympathetic activity and management of associated edema.

Other names
BIA 5-1058 + furosemidezamicastat + furosemide
02

Targets

GABRR (GABA-A receptor subunit rho)NKCC2 (Sodium-potassium-chloride cotransporter 2)ABCG2 (Breast cancer resistance protein)SLCO2B1 (Organic anion transporting polypeptide 2B1)DBH (Dopamine beta-hydroxylase)ABCC4 (Multidrug resistance-associated protein 4)

Beyond the preview

Go deeper on BIA 5-1058 + furosemide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIA 5-1058 + furosemide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call